Dr. Emer Leahy, PhD, MBA
Dr. Leahy holds a PhD in neuropharmacology from University College Dublin, Ireland and an MBA from Columbia University. She is CEO of PsychoGenics Inc., a profitable preclinical CNS service company, and CEO of PGI Drug Discovery LLC, a company engaged in neuropsychiatric drug discovery with four partnered clinical programs including one in Phase III for major neuropsychiatric disorders. She also holds an Adjunct Associate Professor of Neuroscience position at Mount Sinai School of Medicine. Dr. Leahy has more than 30 years of experience in drug discovery, clinical development and business development for pharmaceutical and biotechnology companies, including extensive knowledge of technology assessment, licensing, mergers and acquisitions, and strategic planning. Dr. Leahy serves on the Board of Directors of PsychoGenics Inc., the Board of Directors of Intensity Therapeutics, a clinical stage oncology company, the Board of Directors of Pasithea therapeutics, a public company focused on development of treatments for brain disorders and is Vice Chair of BioNJ., the industry organization representing biopharma in New Jersey.